Sirona Dental Systems (SIRO) 10-Q 9 May 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Mar. 31, 2014	Apr. 30, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Document period end date	31-Mar-14	'
Amendment flag	'false	'
Current fiscal year end date	'--09-30	'
Entity central index key	'0001014507	'
Entity current reporting status	'Yes	'
Entity filer category	'Large Accelerated Filer	'
Entity registrant name	'SIRONA DENTAL SYSTEMS, INC.	'
Entity voluntary filers	'No	'
Entity well known seasoned issuer	'Yes	'
Entity common stock shares outstanding	'	57,647,575
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (USD $)	3 Months Ended		6 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)	'	'	'	'
REVENUE	$282.70	$267.30	$581.40	$539.70
Cost of goods sold	-131.2	-122.6	-267.2	-243.1
GROSS PROFIT	151.5	144.7	314.2	296.6
Selling, general and administrative expense	-87.2	-84.5	-175.2	-170.4
Research and development expense	-16.4	-15.1	-31.5	-29.2
Net other operating income (loss)	2.5	2.5	5	9.4
OPERATING INCOME	50.4	47.6	112.5	106.4
Gain (loss) on foreign currency transactions	2	-1.4	-0.6	-6
Gain (loss) on derivative instruments	-1.5	-2.5	-0.9	-1.2
Interest income (expense)	-0.9	-0.8	-1.7	-1.8
Other income (expense)	-0.4	-0.4	-0.9	-0.7
INCOME BEFORE TAXES	49.6	42.5	108.4	96.7
Income taxes	-11.7	-10.2	-25.5	-25.4
NET INCOME	37.9	32.3	82.9	71.3
Less: Net income attributable to noncontrolling interests	-0.6	-0.5	-1.4	-1.3
NET INCOME ATTRIBUTABLE TO SIRONA DENTAL SYSTEMS, INC.	$37.30	$31.80	$81.50	$70
INCOME PER SHARE (attributable to Sirona Dental Systems, Inc. common shareholders):	'	'	'	'
Basic	$0.67	$0.58	$1.48	$1.27
Diluted	$0.66	$0.56	$1.45	$1.24
Weighted average shares - basic	55,309,421	54,928,332	55,186,566	55,083,264
Weighted average shares - diluted	56,199,246	56,202,296	56,172,320	56,384,483

CONSOLIDATED_STATEMENT_OF_COMP

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)	'	'	'	'
NET INCOME	$37.90	$32.30	$82.90	$71.30
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:	'	'	'	'
Cumulative translation adjustment	1.8	-23.2	17.7	-6.9
Derivative financial hedging instruments	0.1	0.1	0.2	0.2
Unrecognized elements of pension cost	0	-0.3	0.1	-0.2
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	1.9	-23.4	18	-6.9
TOTAL COMPREHENSIVE INCOME (LOSS)	39.8	8.9	100.9	64.4
Comprehensive (income) loss attributable to noncontrolling interests	-0.5	-0.2	-1.4	-1.1
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO SIRONA DENTAL SYSTEMS, INC. SHAREHOLDERS	$39.30	$8.70	$99.50	$63.30

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $)	Mar. 31, 2014	Sep. 30, 2013
In Millions, unless otherwise specified
CURRENT ASSETS	'	'
Cash and cash equivalents	$255.30	$241.70
Restricted cash	0.8	0.7
Accounts receivable, net of allowance for doubtful accounts of $1.6 and $1.6, respectively	151	145.2
Inventories, net	129.7	109.2
Deferred tax assets	32.2	31.4
Prepaid expenses and other current assets	27.4	32.6
Income tax receivable	1.6	2.3
TOTAL CURRENT ASSETS	598	563.1
Property, plant and equipment, net of accumulated depreciation and amortization of $169.0 and $156.7, respectively	228.8	182.7
Goodwill	684.2	672.1
Intangible assets, net of accumulated amortization of $530.2 and $503.1, respectively	287.9	301.7
Other non-current assets	4.8	5.6
Deferred tax assets	17.3	13.2
TOTAL ASSETS	1,821	1,738.40
CURRENT LIABILITIES	'	'
Trade accounts payable	58.2	73.2
Short-term financial liabilities	1.6	0.4
Income taxes payable	9.8	9.3
Deferred tax liabilities	0.7	0.7
Accrued liabilities and deferred income	155	162.5
TOTAL CURRENT LIABILITIES	225.3	246.1
Long-term financial liabilities	78	75
Deferred tax liabilities	129.5	131.5
Other non-current liabilities	27.3	27.4
Pension related provisions	67.4	66
Deferred income	29.8	34.4
TOTAL LIABILITIES	557.3	580.4
SHAREHOLDERS` EQUITY	'	'
Preferred stock ($0.01 par value; 5,000,000 shares authorized; none issued and outstanding)	0	0
Common stock ($0.01 par value; 95,000,000 shares authorized; 57,647,248 shares issued and 55,347,500 shares outstanding at Mar. 31, 2014; 57,213,615 shares issued and 54,999,436 shares outstanding at Sept. 30, 2013)	0.6	0.6
Additional paid-in capital	686.6	674.2
Treasury stock, at cost 2,299,748 shares held at cost at Mar. 31, 2014; 2,214,179 shares held at cost at Sept. 30, 2013	-118.1	-112
Retained earnings	665.7	584.2
Accumulated other comprehensive income (loss)	26.6	8.6
TOTAL SIRONA DENTAL SYSTEMS, INC. SHAREHOLDERS` EQUITY	1,261.40	1,155.60
NONCONTROLLING INTERESTS	2.3	2.4
TOTAL SHAREHOLDERS` EQUITY	1,263.70	1,158
TOTAL LIABILITIES & SHAREHOLDERS` EQUITY	$1,821	$1,738.40

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parentheticals) (USD $)	Mar. 31, 2014	Sep. 30, 2013
In Millions, except Share data, unless otherwise specified
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)	'	'
Allowance for doubtful accounts	$1.60	$1.60
Accumulated depreciation and amortization	169	156.7
Finite-Lived Intangible Assets, Accumulated amortization	$530.20	$503.10
Preferred stock par value per share	$0.01	$0.01
Preferred stock shares authorized	5,000,000	5,000,000
Common stock par value per share	$0.01	$0.01
Common stock shares authorized	95,000,000	95,000,000
Common stock shares issued	57,647,248	57,213,615
Common stock shares outstanding	55,347,500	54,999,436
Treasury stock shares	2,299,748	2,214,179

CONSOLIDATED_STATEMENTS_OF_SHA

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY AND COMPREHENSIVE INCOME (UNAUDITED) (USD $)	Total	COMMON SHARE CAPITAL	ADDITIONAL PAID-IN CAPITAL	TREASURY STOCK	RETAINED EARNINGS	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	TOTAL SIRONA DENTAL SYSTEMS, INC. SHAREHOLDERS` EQUITY	EQUITY ATTRIBUTABLE TO NONCONTROLLING INTERESTS
In Millions, except Share data, unless otherwise specified
Balance at Sep. 30, 2012	'	'	$650.20	($69.10)	$437.50	($29.80)	'	$3
Balance, shares at Sep. 30, 2012	'	55,051,673	'	'	'	'	'	'
NUMBER OF COMMON SHARES ISSUED AND OUTSTANDING	'	'	'	'	'	'	'	'
Issuance of common stock upon exercise of options, shares	'	270,574	'	'	'	'	'	'
Purchase of treasury stock, shares	'	-385,080	'	'	'	'	'	'
SHAREHOLDERS` EQUITY	'	'	'	'	'	'	'	'
Issuance of common stock upon exercise of options and net effect of vesting of RSUs/PSUs	'	'	3.6	'	'	'	'	'
Purchase of treasury stock (at cost)	'	'	'	-23.9	'	'	'	'
Stock Compensation	'	'	8.4	'	'	'	'	'
Tax effect of stock options exercised and net effect of vesting of RSUs/PSUs	'	'	-2.4	'	'	'	'	'
Purchase of shares from noncontrolling interest	'	'	-0.6	'	'	'	'	-0.8
Dividend distribution to noncontrolling interest	'	'	'	'	'	'	'	-1.4
Comprehensive income (loss)	64.4	'	'	'	70	-6.6	'	'
Net income attributable to noncontrolling interests	1.3	'	'	'	'	'	'	1.3
Cumulative translation adjustment	'	'	'	'	'	'	'	-0.3
Balance at Mar. 31, 2013	1,039.70	0.6	659.2	-93	507.5	-36.4	1,037.90	1.8
Balance, shares at Mar. 31, 2013	'	54,937,167	'	'	'	'	'	'
Balance at Sep. 30, 2013	1,158	'	674.2	-112	584.2	8.6	'	2.4
Balance, shares at Sep. 30, 2013	54,999,436	54,999,436	'	'	'	'	'	'
NUMBER OF COMMON SHARES ISSUED AND OUTSTANDING	'	'	'	'	'	'	'	'
Issuance of common stock upon exercise of options, shares	'	433,633	'	'	'	'	'	'
Purchase of treasury stock, shares	'	-85,569	'	'	'	'	'	'
SHAREHOLDERS` EQUITY	'	'	'	'	'	'	'	'
Issuance of common stock upon exercise of options and net effect of vesting of RSUs/PSUs	'	'	5.4	'	'	'	'	'
Purchase of treasury stock (at cost)	'	'	'	-6.1	'	'	'	'
Stock Compensation	'	'	6.4	'	'	'	'	'
Tax effect of stock options exercised and net effect of vesting of RSUs/PSUs	'	'	0.6	'	'	'	'	'
Purchase of shares from noncontrolling interest	'	'	0	'	'	'	'	0
Dividend distribution to noncontrolling interest	'	'	'	'	'	'	'	-1.5
Comprehensive income (loss)	100.9	'	'	'	81.5	18	'	'
Net income attributable to noncontrolling interests	1.4	'	'	'	'	'	'	1.4
Cumulative translation adjustment	'	'	'	'	'	'	'	0
Balance at Mar. 31, 2014	$1,263.70	$0.60	$686.60	($118.10)	$665.70	$26.60	$1,261.40	$2.30
Balance, shares at Mar. 31, 2014	55,347,500	55,347,500	'	'	'	'	'	'

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
OPERATING ACTIVITIES	'	'
NET INCOME	$82.90	$71.30
ADJUSTMENTS TO RECONCILE NET INCOME TO NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	'	'
Depreciation and amortization	37.7	36.5
(Gain) loss on derivative instruments and foreign currency	1.5	7.2
Deferred income taxes	-9.2	5.4
Share-based compensation expense	6.4	8.4
Other adjustments	0.3	0.4
TOTAL ADJUSTMENTS TO RECONCILE NET INCOME TO OPERATING CASH FLOWS	36.7	57.9
CHANGES IN ASSETS AND LIABILITIES	'	'
Accounts receivable	-5.2	2.7
Inventories	-19.9	-25.3
Trade accounts payable	-16.3	16.1
Other current and non-current assets	6	-7.1
Other current and non-current liabilities	-6.4	-21.9
Current income taxes	1.1	-3.9
EFFECT OF CHANGES IN ASSETS AND LIABILITIES ON OPERATING CASH FLOWS	-40.7	-39.4
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	78.9	89.8
INVESTING ACTIVITIES	'	'
Investment in property, plant and equipment	-61.1	-22.3
Proceeds from sale of property, plant and equipment	0.4	0.1
Purchase of intangible assets	-0.2	0
Acquisition of businesses, net of cash acquired	0	-35
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	-60.9	-57.2
FINANCING ACTIVITIES	'	'
Repayments of short-term and long-term debt	0	-0.1
Purchase of treasury stock	-6.1	-23.9
Purchase of shares from noncontrolling interest	0	-0.9
Dividend distributions to noncontrolling interest	-1.5	-1.4
Common shares issued under share based compensation plans	5.4	3.6
Tax effect of common shares issued under share based compensation plans	-3.5	-3.3
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	-5.7	-26
CHANGE IN CASH AND CASH EQUIVALENTS	12.3	6.6
Effect of exchange rate change on cash and cash equivalents	1.3	-1.4
Cash and cash equivalents at beginning of period	241.7	151.1
CASH AND CASH EQUIVALENTS AT END OF PERIOD	255.3	156.3
SUPPLEMENTAL INFORMATION	'	'
Interest paid	1.7	1.6
Interest capitalized	0.2	0.1
Income taxes paid	28.8	32.7
ACQUISITION OF BUSINESS	'	'
Current assets	0	5.2
Non-current assets	0	61.2
Current liabilities	0	-7.8
Non-current liabilities	0	-12
Fair value of total consideration transferred	0	46.6
Cash paid	0	-36.7
Settlement of balances	0	-4.5
Fair value of liabilities incurred	$0	$5.40

General

General	6 Months Ended
	Mar. 31, 2014
General [Abstract]	'
General	'
	1. GENERAL
	The Company and its Operations
	Sirona Dental Systems, Inc. (“Sirona,” the “Company,” “we,” “us,” and “our” refer to Sirona Dental Systems, Inc. and its consolidated subsidiaries) is the leading global manufacturer of high-quality, technologically-advanced dental equipment, and is focused on developing, manufacturing, and marketing innovative systems and solutions for dentists around the world. We offer a broad range of products across all major segments of the dental technology market including CEREC and our other CAD/CAM systems, digital intra oral and 2D and 3D panoramic imaging systems, treatment centers, and instruments. The Company acquired Schick Technologies, Inc. (“Schick”) in 2006, in a transaction accounted for as a reverse acquisition (the “Exchange”), further expanding our global presence and product offerings and strengthening our research and development capabilities. Sirona has served equipment dealers and dentists worldwide for more than 130 years. The Company’s headquarters is located in Long Island City, New York with its primary facility located in Bensheim, Germany, as well as other support, manufacturing, assembling, and sales and service facilities located around the globe.
	Basis of Presentation
	These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Preparation of the interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions related to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as at the reporting date and the reported amounts of revenues and expenses for the interim period. Actual results could differ from those estimates. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information not misleading. The year-end consolidated financial data was derived from the audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These consolidated financial statements should be read in conjunction with the Consolidated Financial Statements and the Notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2013.
	In the opinion of management, all adjustments considered necessary to present fairly the Company’s financial position as of March 31, 2014, and the results of operations and cash flows for the six months ended March 31, 2014 and 2013, respectively, as applicable to interim periods have been made. The results of operations for the six months ended March 31, 2014 are not necessarily indicative of the operating results for the full fiscal year or future periods.
	All amounts are reported in millions of U.S. Dollars ($), except per share amounts or as otherwise disclosed.
	Fiscal year
	The Company’s fiscal year is October 1 to September 30.
	Principles of consolidation
	The consolidated financial statements include, after eliminating inter-company transactions and balances, the accounts of Sirona Dental Systems, Inc. and its subsidiaries. The Company applies the equity method of accounting for investments in associated companies over which the Company has significant influence but does not have effective control.

Employee_ShareBased_Compensati

Employee Share-Based Compensation	6 Months Ended
	Mar. 31, 2014
Employee Share-Based Compensation [Abstract]	'
Employee Share-Based Compensation	'
	2. EMPLOYEE SHARE-BASED COMPENSATION
	ASC 718, Compensation – Stock Compensation, requires that all share based compensation arrangements, including grants of stock option awards to employees, be recognized based on the estimated fair value of the share-based payment award.
	Equity Incentive Plan
	Stock options, restricted stock shares, restricted stock units (“RSU”), and performance-based stock units (“PSU”) have been issued to employees, directors, and consultants under the Company’s 2006 Equity Incentive Plan (“2006 Plan”). The 2006 Plan provides for granting in total up to 4,550,000 stock options, incentive stock, restricted stock shares, RSU’s, and PSU’s. The 2006 Plan received stockholder approval at the Company’s Annual Meeting of Stockholders held on February 27, 2007, and was amended on February 25, 2009. To cover the exercise of options and vesting of RSU’s and PSU’s, the Company generally issues new shares from its authorized but unissued share pool. As of March 31, 2014, 497,074 shares were available for future grant under the 2006 Plan.
	Restricted and Performance-Based Stock Units
	In the six months ended March 31, 2014, the Company granted 149,469 RSU’s and 43,466 PSU’s with an average value of $67.36, representing the average of closing prices of the Company’s common stock at grant dates.
	RSU’s and PSU’s generally vest in annual tranches over a period of three to four years. The PSU’s were granted to certain Company executives and vest three years from the date of the grant provided the Company achieves performance targets specified in the grant. RSU’s and PSU’s do not have voting rights or rights to dividends prior to vesting. The value of each RSU and PSU grant is determined by the closing price at the date of grant. Share-based compensation expense for the entire award is recognized straight-line over the service period of the last separately vesting tranche of the award.
	Stock Options
	In the six months ended March 31, 2014, the Company granted 224,565 stock options with a weighted average exercise price of $67.77 and weighted average fair value of $21.28 at the grant date. Grants generally vest over four years. All grants expire ten years after the date of the grant.
	The fair value of options granted under the 2006 Plan were estimated using the Black-Scholes option pricing model using assumptions in the following table. The exercise price is equal to the fair market value of Sirona’s stock at the grant date. Expected volatility is based on the Company’s historical stock price volatility. The risk-free rate is based on the U.S. Treasury yield curve in effect at the day of grant and has a term equal to the expected life of the option. The expected life represents the period of time the options are expected to be outstanding based on anticipated grantee behavior. The expected dividend yield is based on the Company’s history of not paying regular dividends in the past and the Company’s current intention not to pay dividends in the foreseeable future.
		Black-Scholes Assumptions		Six months ended		Year ended
				March 31,		September 30,
				2014		2013
		Expected Volatility		33.27%		38.23%
		Risk-free rate		1.35%		0.70%
		Expected term		5 years		5 years
		Expected dividends		-		-
	Compensation Costs
	The following table summarizes compensation expense charged to income for stock-based compensation and additional information for the three and six months ended March 31, 2014:
		Compensation Expense		Three months ended				Six months ended
				March 31,				March 31,
		(In millions, except where noted)		2014		2013		2014		2013
		Compensation expense (1), (2)	$	3	$	2.3	$	6.4	$	8.4
		(1) For the first half of fiscal year 2014, this included a compensation charge of $0.9 for share-based awards in connection with the CFO Transition.
		(2) For the first half of fiscal year 2013, this includes a compensation charge of $3.8 for the modification of share based awards in connection with the Transition Agreement for the former CEO and Chairman.
	Restricted and Performance-Based Stock Unit Activity
	The following is a summary of Sirona’s RSU and PSU activity for the six months ended March 31, 2014:
		RSU and PSU Activity		Six months ended
				March 31,
				2014
				Restricted stock units				Performance-based stock units
				Number of shares		Weighted average market price at grant		Number of shares		Weighted average market price at grant
		Outstanding at beginning of period		570,928	$	46.37		13,000	$	36.78
		Granted		149,469		67.57		43,466		66.63
		Vested		-182,329		37.68		-13,000		36.78
		Forfeited		-23,615		48.49		-		0
		Outstanding at end of period		514,453	$	55.51		43,466	$	66.63
	Stock Option Activity
	The following is a summary of Sirona’s stock option activity for the six months ended March 31, 2014:
		Stock Option Activity		Six months ended
				March 31,
		(In millions, except for price and where noted)		2014
				Number of options		Weighted average exercise price
		Outstanding at beginning of period		1,778,102	$	21.93
		Granted		224,565		67.77
		Exercised		-299,155		17.67
		Forfeited		-28,900		51.68
		Outstanding at end of period		1,674,612	$	28.33
		thereof vested and exercisable		1,287,526

Net_Other_Operating_Income_Los

Net Other Operating Income (Loss)	6 Months Ended
	Mar. 31, 2014
Net Other Operating Income (Loss)[Abstract]	'
Net Other Operating Income	'
	3. NET OTHER OPERATING INCOME (LOSS)
	The components of net other operating income (loss) for the periods under report are as follows:
		Net Other Operating Income (Loss)		Three months ended				Six months ended
				March 31,				March 31,
		(In millions)		2014		2013		2014		2013
		Income resulting from the amortization of the deferred income related to the Patterson exclusivity payment	$	2.5	$	2.5	$	5	$	5
		Gain from patent infringement settlement		-		-		-		4.4
		Net other operating income (loss)	$	2.5	$	2.5	$	5	$	9.4
	The gain from a patent infringement settlement for the six months ended March 31, 2013, represents amounts received related to prior years.

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging Strategies	6 Months Ended
	Mar. 31, 2014
Derivative Instruments And Hedging Strategies [Abstract]	'
Derivative Instruments and Hedging Strategies	'
	4. DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
	Our operations are exposed to market risks from changes in foreign currency exchange rates and interest rates. In the normal course of business, these risks are managed through a variety of strategies, including the use of derivatives.
	Interest Rate Risk
	The Company is exposed to interest rate risk associated with fluctuations in the interest rates on its variable interest rate debt. In order to manage this risk, the Company enters into interest rate swap agreements, when appropriate, based upon market conditions.
	Foreign Currency Exposure
	Although the U.S. Dollar is Sirona’s reporting currency, it conducts its business in many currencies, and its local functional currency varies depending on the country of operation, which exposes the Company to market risk associated with foreign currency exchange rate movements. The Company hedges certain foreign currency transaction exposure through foreign exchange forward contracts.
	Cash Flow Hedges
	Interest Rate
	The Company uses interest rate swaps to convert a portion of its debt's variable interest rate to a fixed interest rate. Interest rate swaps have been established for 100% of the interest for the Facility A Term Loan under the New Senior Facilities Agreement until November 2016. The interest rate swaps fix the LIBOR element of interest payable on 100% of the principal amount of the Facility A Term Loan for defined three month interest periods over the entire term of the loan. The defined interest rates fixed for each three month interest period range from 1.270% to 1.285%. Settlement of the swaps is required on a quarterly basis. These swaps are designated as hedging instruments under ASC 815. The Company enters into interest rate swap contracts infrequently as they are only used to manage interest rate risk on long-term debt instruments.
	Foreign Currency
	The Euro is the functional currency for many of Sirona’s subsidiaries, including its primary sales and manufacturing operations in Germany. During the periods under review, the U.S. Dollar/Euro exchange rate fluctuated significantly, thereby impacting Sirona’s financial results. In order to hedge portions of the transactional exposure to fluctuations in exchange rates, based on forecasted and firmly-committed cash flows, Sirona enters into foreign exchange forward contracts (currently: USD, AUD, and JPY). These forward foreign currency contracts are intended to reduce short-term effects of changes in exchange rates. The Company enters into forward contracts that are considered to be economic hedges but which are not considered hedging instruments under ASC 815. As of March 31, 2014, these contracts had notional amounts totaling $ 55.4 million. These agreements are relatively short-term (generally not exceeding six months).
	The fair value carrying amount of the Company's derivative instruments at March 31, 2014 is described in Note 15 Fair Value Measurements.
	The following tables summarize the impact of gains and losses from the fair value changes of the Company’s derivative instruments reported in our condensed consolidated statements of income for the
		Derivatives Designated as Cash Flow Hedging Instruments
		Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Income		For the three months ended				For the six months ended
				March 31,				March 31,
		(In millions)		2014		2013		2014		2013
		Interest rate swap contracts	$	0.1	$	0.2	$	0.2	$	0.4
		Derivatives Not Designated as Hedging Instruments
		Amount of Gain (Loss) Recognized in Income on Derivative Instruments		For the three months ended				For the six months ended
				March 31,				March 31,
		(In millions)		2014		2013		2014		2013	Affected Line Item in the Statement of Income
		Foreign exchange contracts	$	-1.5	$	-2.5	$	-0.9	$	-1.2	Gain (loss) on derivative instruments, net

Income_Taxes

Income Taxes	6 Months Ended
	Mar. 31, 2014
Income Taxes [Abstract]	'
Income Taxes	'
	5. INCOME TAXES
	For the first six months of fiscal year 2014, an estimated effective tax rate of 23.5% has been applied. The income tax provision for the first six months ended March 31, 2014, was $ 25.5 million. For the first six months of fiscal year 2013, a 24.0% estimated effective tax rate was applied. Additionally, a tax expense was recorded for $2.2 million from a non-cash remeasurement of deferred tax assets and liabilities resulting from a local trade tax rate increase at our principal German operations, which was enacted and was effective in the first quarter of fiscal year 2013. Excluding this amount, the effective tax rate for fiscal year 2013 was 23.7%.
	The Company's effective tax rate may vary significantly from period to period, and can be influenced by many factors. These factors include, but are not limited to, changes to statutory tax rates in the jurisdictions where the Company has operations, changes in the mix of earnings amongst jurisdictions with differing statutory tax rates (including as a result of business acquisitions and dispositions), changes in the valuation of deferred tax assets and liabilities, the results of audits and examinations of previously filed tax returns, tax planning initiatives, tax characteristics of income, as well as the timing and deductibility of expenses for tax purposes. The Company's effective tax rate differs from the U.S. federal statutory rate of 35% primarily as a result of lower statutory tax rates on foreign earnings at the Company’s operations outside of the United States. The distribution of lower-taxed foreign earnings to the U.S. would generally increase the Company's effective tax rate.
	With limited exception, the Company and its subsidiaries are no longer subject to U.S. federal, state and local or non-U.S. income tax examinations by taxing authorities for tax returns filed with respect to periods prior to fiscal year 2009.
	The Company makes no provision for deferred U.S. income taxes on undistributed foreign earnings because as of March 31, 2014, it remained management’s intention to continue to indefinitely reinvest such earnings in foreign operations. In making this determination, the Company also evaluates its expected cash requirements in the United States. These earnings relate to ongoing operations and, as of March 31, 2014, the approximate amount of undistributed foreign earnings amounted to $448 million. Because of the availability of U.S. foreign tax credits as well as other factors, it is not practicable to determine the income tax liability that would be payable if such earnings were not reinvested indefinitely.

Income_per_Share

Income per Share	6 Months Ended
	Mar. 31, 2014
Income per Share [Abstract]	'
Income per Share	'
	6. INCOME PER SHARE
	The computation of basic and diluted income per share is as follows:
		Income per Share		Three months ended				Six months ended
				March 31,				March 31,
		(In millions, except share and per share amounts)		2014		2013		2014		2013
		Net income attributable to Sirona Dental Systems, Inc. common shareholders	$	37.3	$	31.8	$	81.5	$	70
		Weighted average shares outstanding - basic		55,309,421		54,928,332		55,186,566		55,083,264
		Dilutive effect of stock-based compensation		889,825		1,273,964		985,754		1,301,219
		Weighted average shares outstanding - diluted		56,199,246		56,202,296		56,172,320		56,384,483
		Net income per share
		Basic	$	0.67	$	0.58	$	1.48	$	1.27
		Diluted	$	0.66	$	0.56	$	1.45	$	1.24
	There were no stock options excluded from the computation of diluted earnings per share for the three and six months ended March 31, 2014 and March 31, 2013.

Segment_Reporting

Segment Reporting	6 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment reporting	'
	7. SEGMENT REPORTING
	The following tables reflect the results of the Company’s reportable segments under the Company’s management reporting system. The segment performance measure used to monitor segment performance is gross profit (‘‘Segment Performance Measure’’) excluding the impact of the acquisition of control of the Sirona business by Sirona Holdings Luxco S.C.A. (“Luxco”) – the former controlling shareholder, a Luxembourg-based holding entity owned by funds managed by Madison Dearborn Partners (“MDP”); Beecken Petty O’Keefe and management of Sirona through a leveraged buyout transaction on June 30, 2005 (the “MDP Transaction”); and the Exchange. This measure is considered by management to better reflect the performance of each segment as it eliminates the need to allocate centrally incurred costs and significant purchase accounting impacts that the Company does not believe are representative of the performance of the segments. Furthermore, the Company monitors performance geographically by region. As the Company manages its business on both a product and a geographical basis, U.S. GAAP requires segmental disclosure based on product information.
		Segment Performance		Three months ended				Six months ended
				March 31,				March 31,
		(In millions)		2014		2013		2014		2013
		Revenue External
		Dental CAD/CAM Systems	$	108.9	$	103.6	$	214.7	$	199.2
		Imaging Systems		87.9		83.6		193.7		180.6
		Treatment Centers		57.1		54.7		111.5		108.1
		Instruments		28.8		25.4		61.5		51.8
		Total	$	282.7	$	267.3	$	581.4	$	539.7
		Segment performance measure
		Dental CAD/CAM Systems	$	73	$	69.8	$	146.3	$	137.4
		Imaging Systems		49.7		49.8		111.2		108.1
		Treatment Centers		23.5		21.9		44.7		43.1
		Instruments		11.2		10.8		24.7		23
		Total Segments		157.4		152.3		326.9		311.6
	Reconciliation of the results of the segment performance measure to the consolidated statements of operations
	The following table provides a reconciliation of the total results of operations of the Company’s business segments under management reporting to the consolidated financial statements. The differences shown between management reporting and U.S. GAAP for the three and six months ended March 31, 2014 and 2013 are due to the impact of purchase accounting and certain other corporate items. These effects are not included in the segment performance measure as the Company does not believe these to be representative of the performance of each segment.
		Reconciliation of Segment Performance Measure to Consolidated Statement of Operations		Three months ended				Six months ended
				March 31,				March 31,
		(In millions)		2014		2013		2014		2013
		Consolidated revenue	$	282.7	$	267.3	$	581.4	$	539.7
		Segment performance measure
		Total segments		157.4		152.3		326.9		311.6
		Differences management reporting vs. U.S. GAAP (including step-up depreciation and amortization and certain other corporate items)		-5.9		-7.6		-12.7		-15
		Consolidated gross profit		151.5		144.7		314.2		296.6
		Selling, general and administrative expense		-87.2		-84.5		-175.2		-170.4
		Research and development expense		-16.4		-15.1		-31.5		-29.2
		Net other operating income (loss)		2.5		2.5		5		9.4
		Gain (loss) on foreign currency transactions		2		-1.4		-0.6		-6
		Gain (loss) on derivative instruments		-1.5		-2.5		-0.9		-1.2
		Interest income (expense)		-0.9		-0.8		-1.7		-1.8
		Other income (expense)		-0.4		-0.4		-0.9		-0.7
		Income before taxes	$	49.6	$	42.5	$	108.4	$	96.7
	Concentration of Revenue
	A substantial portion of our revenue comes from two distributors accounting for more than 10% of revenues. Patterson Companies, Inc. (“Patterson”) and Henry Schein, Inc. (“Henry Schein”) accounted for revenues and accounts receivable for the three and six months ended March 31, 2014 compared to the three and six months ended March 31, 2013 as shown in the table below. These revenues were earned across all segments, with a significant portion of revenues with Patterson being earned in the CAD/CAM and Imaging segments. No other customer accounted for more than 10% of revenues.
		Concentration of Revenue		Three months ended				Six months ended
				March 31,				March 31,
		(In millions, except for percent amounts)		2014		2013		2014		2013
		Top Customers
		Revenues
		Patterson Dental Company, Inc.		29%		32%		31%		33%
		Henry Schein, Inc.		13%		15%		13%		14%
		Total of customers > 10% revenues		42%		47%		44%		47%
		Accounts Receivable
		Patterson Dental Company, Inc.					$	46.9	$	45.7
		Henry Schein, Inc.						9.1		8.2
		Total Accounts Receivable of customers > 10% revenues					$	56	$	53.9

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income/(Loss)	6 Months Ended
	Mar. 31, 2014
Accumulated Other Comprehensive Income/(Loss) [Abstract]	'
Accumulated Other Comprehensive Income	'
	8. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
	The components and development of accumulated other comprehensive income (loss) for the periods under report are as follows:
		Accumulated Other Comprehensive Income (Loss)		Three months ended
				March 31,
				2014
		(In millions)		Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain (loss) from hedging instruments		Total
		Balance at beginning of period	$	18.7	$	6.5	$	-0.6	$	24.6
		Current increase (decrease)		1.8		-		0.1		1.9
		Balance at end of period		20.5		6.5		-0.5		26.5
		Other comprehensive income (loss) attributable to noncontrolling interests, net of tax		-0.1		-		-		-0.1
		Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	20.6	$	6.5	$	-0.5	$	26.6
		Accumulated Other Comprehensive Income (Loss)		Three months ended
				March 31,
				2013
		(In millions)		Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain (loss) from hedging instruments		Total
		Balance at beginning of period	$	-17.8	$	5.6	$	-1.1	$	-13.3
		Current increase (decrease)		-23.2		-0.3		0.2		-23.3
		Income tax (expense) benefit		-		-		-0.1		-0.1
		Balance at end of period		-41		5.3		-1		-36.7
		Other comprehensive income (loss) attributable to noncontrolling interests, net of tax		-0.3		-		-		-0.3
		Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	-40.7	$	5.3	$	-1	$	-36.4
		Accumulated Other Comprehensive Income (Loss)		Six months ended
				March 31,
				2014
		(In millions)		Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain (loss) from hedging instruments		Total
		Balance at beginning of period	$	2.9	$	6.4	$	-0.7	$	8.6
		Current increase (decrease)		17.7		0.1		0.2		18
		Balance at end of period		20.6		6.5		-0.5		26.6
		Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	20.6	$	6.5	$	-0.5	$	26.6
		Accumulated Other Comprehensive Income (Loss)		Six months ended
				March 31,
				2013
		(In millions)		Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain (loss) from hedging instruments		Total
		Balance at beginning of period	$	-34	$	5.5	$	-1.2	$	-29.7
		Current increase (decrease)		-6.9		-0.2		0.4		-6.7
		Income tax (expense) benefit		-		-		-0.2		-0.2
		Balance at end of period		-40.9		5.3		-1		-36.6
		Other comprehensive income (loss) attributable to noncontrolling interests, net of tax		-0.2		-		-		-0.2
		Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	-40.7	$	5.3	$	-1	$	-36.4

Inventories_net

Inventories, net	6 Months Ended
	Mar. 31, 2014
Inventories, net [Abstract]	'
Inventories, net	'
	9. INVENTORIES, NET
	The components of net inventories for the periods under report are as follows:
		Inventories		March 31,		September 30,
		(In millions)		2014		2013
		Finished goods	$	94.7	$	72.6
		Work in progress		13.2		14.4
		Raw materials		40.8		37.5
		Inventories, gross		148.7		124.5
		Inventory reserve		-19		-15.3
		Inventories, net	$	129.7	$	109.2

Intangible_Assets_and_Goodwill

Intangible Assets and Goodwill	6 Months Ended
	Mar. 31, 2014
Intangible Assets And Goodwill [Abstract]	'
Intangible Assets and Goodwill	'
	11. INTANGIBLE ASSETS AND GOODWILL
	The components and development of intangible assets and goodwill for the periods under report are as follows:
		Intangible Assets		March 31,						September 30,
				2014						2013
						Accum.						Accum.
		(In millions)		Gross		amort.		Net		Gross		amort.		Net
		Patents & Licenses	$	155.5	$	-107.5	$	48	$	152.2	$	-99.1	$	53.1
		Trademarks		133.1		-0.8		132.3		130.8		-0.8		130
		Technologies and dealer relationships		498.3		-421.9		76.4		491.3		-403.2		88.1
		In-process research & development (IPR&D)		31.2		-		31.2		30.5		-		30.5
				818.1		-530.2		287.9		804.8		-503.1		301.7
		Goodwill		684.2		-		684.2		672.1		-		672.1
		Total intangible assets	$	1,502.30	$	-530.2	$	972.1	$	1,476.90	$	-503.1	$	973.8
	The change in the value of intangible assets from September 30, 2013 to March 31, 2014, is mainly attributable to (i) normal amortization for the current fiscal year and (ii) foreign currency fluctuations, with an impact of $ 15.6 million
	The total carrying value of IPR&D of $ 31.2 million as of March 31, 2014, represented a single project. The remaining estimated cost to complete the project was $3.0 million. The project is 65% through the development phase; the remaining steps prior to product release are further development, prototype finalization and testing, integration and field testing, and regulatory approvals. The percentage of completion for the full project is 50%, and we anticipate project completion in the second half of 2015.

ShortTerm_Financial_Liabilitie

Short-Term Financial Liabilities	6 Months Ended
	Mar. 31, 2014
Short-Term Financial Liabilities [Abstract]	'
Short-Term Financial Liabilities	'
	11. SHORT-TERM FINANCIAL LIABILITIES
	The components of short-term financial liabilities for the periods under report are as follows:
		Short-Term Financial Liabilities		March 31,		September 30,
		(In millions)		2014		2013
		Bank loans
		Accrued interest on long-term bank loans	$	0.3	$	0.3
		Other short-term bank loans		0.2		0.1
		Bank loans		0.5		0.4
		Other short-term financial liabilities		1.1		-
		Short-Term Financial Liabilities	$	1.6	$	0.4

Product_Warranty

Product Warranty	6 Months Ended
	Mar. 31, 2014
Product warranty [Abstract]	'
Product warranty	'
	12. PRODUCT WARRANTY
	The following table provides the components of and changes in the product warranty accrual for the periods under report:
		Product Warranty		Three months ended				Six months ended
				March 31,				March 31,
		(In millions)		2014		2013		2014		2013
		Balance at beginning of the period	$	10.2	$	8.5	$	9.7	$	8.5
		Accruals for warranties issued		4.9		5.3		10.5		9.2
		Warranty settlements made		-5.1		-4.9		-10.4		-8.9
		Translation adjustment		-		-0.2		0.2		-0.1
		Balance at end of the period	$	10	$	8.7	$	10	$	8.7

LongTerm_Financial_Liabilities

Long-Term Financial Liabilities	6 Months Ended
	Mar. 31, 2014
Long-Term Financial Liabilities [Abstract]	'
Long-Term Financial Liabilities	'
	13. LONG-TERM FINANCIAL LIABILITIES
	The components of long-term financial liabilities for the periods under report are as follows:
		Long-Term Financial Liabilities		March 31,		September 30,
		(In millions, except percentages)		2014		2013
		Bank loans
		New Senior Term Loan ("Facility A" Term Loan, variable rate)
		repayable in two installments in November 2015 and November 2016	$	75.3	$	75.3
		(Actual interest rate as of March 31, 2014: 2.8775%)
		Bank loans		75.3		75.3
		Other long-term financial liabilities		3		-
				78.3		75.3
		Less current portion		-0.3		-0.3
		Long-Term Financial Liabilities	$	78	$	75
	Senior Term Loans
	New Senior Facilities Agreement
	On November 14, 2011, the Company entered into a new senior facilities agreement (the “New Senior Facilities Agreement”) with Sirona Dental Systems, Inc. and all significant subsidiaries of Sirona as original borrowers and original guarantors. As of November 16, 2011, Sirona fully repaid its obligations under the Prior Senior Facilities Agreement. Initial borrowings under the New Senior Facilities Agreement were used to retire the outstanding borrowings under the Company's previous credit facilities.
	The New Senior Facilities Agreement includes: (1)  a term loan in an aggregate principal amount of $75 million (the "Facility A Term Loan") available to Sirona or Sirona Dental, as borrower; (2)  a 120 million Euro revolving credit facility (“Revolving Facility B”) available to Sirona Dental Systems GmbH and Sirona Dental Services GmbH, as initial borrowers; and (3)  a $100 million revolving credit facility (“Revolving Facility C”) available to Sirona or Sirona Dental, as initial borrowers. The Revolving Facility B is available for borrowing in Euro or any other freely available currency agreed to by the facility agent. The facilities are made available on an unsecured basis. Subject to certain limitations, each European guarantor guarantees the performance of each European borrower, except itself, and each U.S. guarantor guarantees the performance of each U.S. borrower, except itself. There are no cross-border guarantees.
	Of the amount borrowed under the Facility A Term Loan, 30% is due on November 16, 2015, and the balance is due on November 16, 2016. The loans under the New Senior Facilities Agreement bear interest of EURIBOR, for Euro-denominated loans, and LIBOR for the other loans, plus an initial margin of 160, 85 and 110 basis points for the Facility A Term Loan, Revolving Facility B and Revolving Facility C, respectively.
	The New Senior Facilities Agreement contains a margin ratchet. Pursuant to this provision, which applies from March 31, 2012 onwards, the applicable margin varies depending on the Company’s leverage multiple (i.e. the ratio of consolidated total net debt to consolidated adjusted EBITDA as defined in the New Senior Facilities Agreement) between 160 basis points and 215 basis points for the Facility A Term Loan, 85 basis points and 140 basis points for the Revolving Facility B, and 110 basis points and 165 basis points for the Revolving Facility C.
	The New Senior Facilities Agreement contains restrictive covenants that limit Sirona's ability to make loans, to incur additional indebtedness, and to make disposals, subject to agreed-upon exceptions. The Company has agreed to certain financial debt covenants in relation to the financing. The covenants stipulate that the Company must maintain certain ratios in respect of consolidated total net debt to consolidated adjusted EBITDA. If the Company breaches these covenants, the loans will become repayable on demand.
	On November 16, 2011, Sirona entered into 5-year payer interest rate swaps to fully hedge its 3-month LIBOR exposure for the Facility A Term Loan. The terms of the swap reflect the term structure of the underlying loan. The effective nominal interest rate is 1.2775% plus the applicable margin. Settlement of the swaps is required on a quarterly basis.
	Debt issuance costs of $2.8 million were incurred in relation to the financing in November 2011 and have been capitalized as deferred charges and are amortized using the effective interest method over the term of the loans.

Pension_Plans

Pension Plans	6 Months Ended
	Mar. 31, 2014
Pension Plans [Abstract]	'
Pension Plans	'
	14. PENSION PLANS
	The components of net periodic benefit costs for the periods under report are as follows:
		Components of Net Benefit Costs		Three months ended				Six months ended
				March 31,				March 31,
		(In millions)		2014		2013		2014		2013
		Service cost, net	$	-	$	-	$	-0.1	$	-0.1
		Interest cost		-0.6		-0.6		-1.1		-1.1
		Amortization of actuarial gain (loss)		-		-0.1		-0.1		-0.1
		Net periodic benefit cost	$	-0.6	$	-0.7	$	-1.3	$	-1.3

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	15. FAIR VALUE MEASUREMENTS
	The Company applies the provisions of ASC 820, Fair Value Measurements and Disclosures, for assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded or disclosed at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions, and the credit risk of the Company and counterparties to the arrangement.
	ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is available and significant to the fair value measurement. ASC 820 establishes and prioritizes the following three levels of inputs that may be used to measure fair value:
	Level 1
	Quoted prices in active markets for identical assets or liabilities.
	Level 2
	Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3
	Inputs that are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability.
	Assets/Liabilities Measured at Fair Value on a Recurring Basis
	The following table presents the Company’s assets and liabilities measured at fair value on a recurring basis for the periods under report:
		Assets and Liabilities Measured at Fair Value - Recurring Basis		March 31,
				2014
				Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
		(In millions)				Foreign Exchange
		Assets
		Cash Equivalents (money market funds)	$	137.7	$	-	$	-	$	137.7
		Derivative Assets		-		0.4		-		0.4
		Liabilities
		Derivative Liabilities		-		-0.4		-		-0.4
		Business Acquisition-related liabilities		-		-		-13.9		-13.9
		Total	$	137.7	$	-	$	-13.9	$	123.8
		Assets and Liabilities Measured at Fair Value - Recurring Basis		September 30,
				2013
				Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
		(In millions)				Foreign Exchange
		Assets
		Cash Equivalents (money market funds)	$	31.3	$	-	$	-	$	31.3
		Derivative Assets		-		0.9		-		0.9
		Liabilities
		Derivative Liabilities		-		-0.1		-		-0.1
		Business Acquisition-related liabilities		-		-		-13.4		-13.4
		Total	$	31.3	$	0.8	$	-13.4	$	18.7
	The change in the fair value of the business acquisition-related liabilities was $0.5 million, and a total for all acquisitions of $0.3 million and $0.7 million was recorded in other income (expense) in the income statement for the three and six months ended March 31, 2014, respectively.
	In the Company’s March 31, 2014 and September 30, 2013 Condensed Consolidated Balance Sheet, derivative assets and derivative liabilities are classified as prepaid expenses and other current assets and accrued liabilities and deferred income, respectively.
	The Company did not elect the fair value option for any other eligible financial instruments.
	Fair value of financial instruments
	Financial instruments consist of cash, cash equivalents, accounts receivable, accounts payable, foreign currency forward contracts, interest rate swaps, and certain liabilities related to business acquisitions primarily resulting from earn-out features. The carrying amounts of cash, cash equivalents, accounts receivable and accounts payable approximate their respective fair values because of the short maturity and nature of these items. The fair value of the foreign currency forward contracts and interest rate swaps is determined by the estimated cash flows of those contracts and swaps. The fair values of the acquisition-related liabilities are based on discounted valuations of commercial assumptions made by Company management of stipulations governed in the underlying purchase agreements.

General_Policies

General (Policies)	6 Months Ended
	Mar. 31, 2014
General [Abstract]	'
The Company and its Operations	'
	The Company and its Operations
	Sirona Dental Systems, Inc. (“Sirona,” the “Company,” “we,” “us,” and “our” refer to Sirona Dental Systems, Inc. and its consolidated subsidiaries) is the leading global manufacturer of high-quality, technologically-advanced dental equipment, and is focused on developing, manufacturing, and marketing innovative systems and solutions for dentists around the world. We offer a broad range of products across all major segments of the dental technology market including CEREC and our other CAD/CAM systems, digital intra oral and 2D and 3D panoramic imaging systems, treatment centers, and instruments. The Company acquired Schick Technologies, Inc. (“Schick”) in 2006, in a transaction accounted for as a reverse acquisition (the “Exchange”), further expanding our global presence and product offerings and strengthening our research and development capabilities. Sirona has served equipment dealers and dentists worldwide for more than 130 years. The Company’s headquarters is located in Long Island City, New York with its primary facility located in Bensheim, Germany, as well as other support, manufacturing, assembling, and sales and service facilities located around the globe.
Basis of Presentation	'
	Basis of Presentation
	These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Preparation of the interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions related to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as at the reporting date and the reported amounts of revenues and expenses for the interim period. Actual results could differ from those estimates. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information not misleading. The year-end consolidated financial data was derived from the audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These consolidated financial statements should be read in conjunction with the Consolidated Financial Statements and the Notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2013.
	In the opinion of management, all adjustments considered necessary to present fairly the Company’s financial position as of March 31, 2014, and the results of operations and cash flows for the six months ended March 31, 2014 and 2013, respectively, as applicable to interim periods have been made. The results of operations for the six months ended March 31, 2014 are not necessarily indicative of the operating results for the full fiscal year or future periods.
	All amounts are reported in millions of U.S. Dollars ($), except per share amounts or as otherwise disclosed.
Fiscal year	'
	Fiscal year
	The Company’s fiscal year is October 1 to September 30.
Principles of consolidation	'
	Principles of consolidation
	The consolidated financial statements include, after eliminating inter-company transactions and balances, the accounts of Sirona Dental Systems, Inc. and its subsidiaries. The Company applies the equity method of accounting for investments in associated companies over which the Company has significant influence but does not have effective control.
Derivative Instruments and Hedging Strategies	'
	DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
	Our operations are exposed to market risks from changes in foreign currency exchange rates and interest rates. In the normal course of business, these risks are managed through a variety of strategies, including the use of derivatives.
	Interest Rate Risk
	The Company is exposed to interest rate risk associated with fluctuations in the interest rates on its variable interest rate debt. In order to manage this risk, the Company enters into interest rate swap agreements, when appropriate, based upon market conditions.
	Foreign Currency Exposure
	Although the U.S. Dollar is Sirona’s reporting currency, it conducts its business in many currencies, and its local functional currency varies depending on the country of operation, which exposes the Company to market risk associated with foreign currency exchange rate movements. The Company hedges certain foreign currency transaction exposure through foreign exchange forward contracts.
	Interest Rate
	The Company uses interest rate swaps to convert a portion of its debt's variable interest rate to a fixed interest rate.
Fair Value of Financial Instruments	'
	Fair value of financial instruments
	Financial instruments consist of cash, cash equivalents, accounts receivable, accounts payable, foreign currency forward contracts, interest rate swaps, and certain liabilities related to business acquisitions primarily resulting from earn-out features. The carrying amounts of cash, cash equivalents, accounts receivable and accounts payable approximate their respective fair values because of the short maturity and nature of these items. The fair value of the foreign currency forward contracts and interest rate swaps is determined by the estimated cash flows of those contracts and swaps. The fair values of the acquisition-related liabilities are based on discounted valuations of commercial assumptions made by Company management of stipulations governed in the underlying purchase agreements.

Employee_ShareBased_Compensati1

Employee Share-Based Compensation (Tables)	6 Months Ended
	Mar. 31, 2014
Employee Share-Based Compensation [Abstract]	'
Schedule of Black-Scholes assumptions (option pricing)	'
		Black-Scholes Assumptions		Six months ended		Year ended
				March 31,		September 30,
				2014		2013
		Expected Volatility		33.27%		38.23%
		Risk-free rate		1.35%		0.70%
		Expected term		5 years		5 years
		Expected dividends		-		-
Schedule of compensation expense and other information	'
		Compensation Expense		Three months ended				Six months ended
				March 31,				March 31,
		(In millions, except where noted)		2014		2013		2014		2013
		Compensation expense (1), (2)	$	3	$	2.3	$	6.4	$	8.4
		(1) For the first half of fiscal year 2014, this included a compensation charge of $0.9 for share-based awards in connection with the CFO Transition.
		(2) For the first half of fiscal year 2013, this includes a compensation charge of $3.8 for the modification of share based awards in connection with the Transition Agreement for the former CEO and Chairman.
Schedule of restricted and performance-based stock unit activity	'
		RSU and PSU Activity		Six months ended
				March 31,
				2014
				Restricted stock units				Performance-based stock units
				Number of shares		Weighted average market price at grant		Number of shares		Weighted average market price at grant
		Outstanding at beginning of period		570,928	$	46.37		13,000	$	36.78
		Granted		149,469		67.57		43,466		66.63
		Vested		-182,329		37.68		-13,000		36.78
		Forfeited		-23,615		48.49		-		0
		Outstanding at end of period		514,453	$	55.51		43,466	$	66.63
Schedule of stock option activity	'
		Stock Option Activity		Six months ended
				March 31,
		(In millions, except for price and where noted)		2014
				Number of options		Weighted average exercise price
		Outstanding at beginning of period		1,778,102	$	21.93
		Granted		224,565		67.77
		Exercised		-299,155		17.67
		Forfeited		-28,900		51.68
		Outstanding at end of period		1,674,612	$	28.33
		thereof vested and exercisable		1,287,526

Net_Other_Operating_Income_Los1

Net Other Operating Income (Loss) (Table)	6 Months Ended
	Mar. 31, 2014
Net Other Operating Income (Loss)[Abstract]	'
Schedule Of Net Other Operating Income Table [Text Block]	'
		Net Other Operating Income (Loss)		Three months ended				Six months ended
				March 31,				March 31,
		(In millions)		2014		2013		2014		2013
		Income resulting from the amortization of the deferred income related to the Patterson exclusivity payment	$	2.5	$	2.5	$	5	$	5
		Gain from patent infringement settlement		-		-		-		4.4
		Net other operating income (loss)	$	2.5	$	2.5	$	5	$	9.4

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Strategies (Tables)	6 Months Ended
	Mar. 31, 2014
Derivative Instruments And Hedging Strategies [Abstract]	'
Schedule of derivative instruments, location and amount of gains and losses	'
		Derivatives Designated as Cash Flow Hedging Instruments
		Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Income		For the three months ended				For the six months ended
				March 31,				March 31,
		(In millions)		2014		2013		2014		2013
		Interest rate swap contracts	$	0.1	$	0.2	$	0.2	$	0.4
		Derivatives Not Designated as Hedging Instruments
		Amount of Gain (Loss) Recognized in Income on Derivative Instruments		For the three months ended				For the six months ended
				March 31,				March 31,
		(In millions)		2014		2013		2014		2013	Affected Line Item in the Statement of Income
		Foreign exchange contracts	$	-1.5	$	-2.5	$	-0.9	$	-1.2	Gain (loss) on derivative instruments, net

Income_per_Share_Tables

Income per Share (Tables)	6 Months Ended
	Mar. 31, 2014
Income per Share [Abstract]	'
Schedule of income per share	'
		Income per Share		Three months ended				Six months ended
				March 31,				March 31,
		(In millions, except share and per share amounts)		2014		2013		2014		2013
		Net income attributable to Sirona Dental Systems, Inc. common shareholders	$	37.3	$	31.8	$	81.5	$	70
		Weighted average shares outstanding - basic		55,309,421		54,928,332		55,186,566		55,083,264
		Dilutive effect of stock-based compensation		889,825		1,273,964		985,754		1,301,219
		Weighted average shares outstanding - diluted		56,199,246		56,202,296		56,172,320		56,384,483
		Net income per share
		Basic	$	0.67	$	0.58	$	1.48	$	1.27
		Diluted	$	0.66	$	0.56	$	1.45	$	1.24

Segment_reporting_Tables

Segment reporting (Tables)	6 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Schedule of segment reporting information by segment	'
		Segment Performance		Three months ended				Six months ended
				March 31,				March 31,
		(In millions)		2014		2013		2014		2013
		Revenue External
		Dental CAD/CAM Systems	$	108.9	$	103.6	$	214.7	$	199.2
		Imaging Systems		87.9		83.6		193.7		180.6
		Treatment Centers		57.1		54.7		111.5		108.1
		Instruments		28.8		25.4		61.5		51.8
		Total	$	282.7	$	267.3	$	581.4	$	539.7
		Segment performance measure
		Dental CAD/CAM Systems	$	73	$	69.8	$	146.3	$	137.4
		Imaging Systems		49.7		49.8		111.2		108.1
		Treatment Centers		23.5		21.9		44.7		43.1
		Instruments		11.2		10.8		24.7		23
		Total Segments		157.4		152.3		326.9		311.6
Schedule of reconciliation of operating profit (loss) from segments to consolidated	'
		Reconciliation of Segment Performance Measure to Consolidated Statement of Operations		Three months ended				Six months ended
				March 31,				March 31,
		(In millions)		2014		2013		2014		2013
		Consolidated revenue	$	282.7	$	267.3	$	581.4	$	539.7
		Segment performance measure
		Total segments		157.4		152.3		326.9		311.6
		Differences management reporting vs. U.S. GAAP (including step-up depreciation and amortization and certain other corporate items)		-5.9		-7.6		-12.7		-15
		Consolidated gross profit		151.5		144.7		314.2		296.6
		Selling, general and administrative expense		-87.2		-84.5		-175.2		-170.4
		Research and development expense		-16.4		-15.1		-31.5		-29.2
		Net other operating income (loss)		2.5		2.5		5		9.4
		Gain (loss) on foreign currency transactions		2		-1.4		-0.6		-6
		Gain (loss) on derivative instruments		-1.5		-2.5		-0.9		-1.2
		Interest income (expense)		-0.9		-0.8		-1.7		-1.8
		Other income (expense)		-0.4		-0.4		-0.9		-0.7
		Income before taxes	$	49.6	$	42.5	$	108.4	$	96.7
Schedule of concentration of revenue	'
		Concentration of Revenue		Three months ended				Six months ended
				March 31,				March 31,
		(In millions, except for percent amounts)		2014		2013		2014		2013
		Top Customers
		Revenues
		Patterson Dental Company, Inc.		29%		32%		31%		33%
		Henry Schein, Inc.		13%		15%		13%		14%
		Total of customers > 10% revenues		42%		47%		44%		47%
		Accounts Receivable
		Patterson Dental Company, Inc.					$	46.9	$	45.7
		Henry Schein, Inc.						9.1		8.2
		Total Accounts Receivable of customers > 10% revenues					$	56	$	53.9

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Mar. 31, 2014
Accumulated Other Comprehensive Income/(Loss) [Abstract]	'
Schedule of Comprehensive Income (Loss)	'
		Accumulated Other Comprehensive Income (Loss)		Three months ended
				March 31,
				2014
		(In millions)		Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain (loss) from hedging instruments		Total
		Balance at beginning of period	$	18.7	$	6.5	$	-0.6	$	24.6
		Current increase (decrease)		1.8		-		0.1		1.9
		Balance at end of period		20.5		6.5		-0.5		26.5
		Other comprehensive income (loss) attributable to noncontrolling interests, net of tax		-0.1		-		-		-0.1
		Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	20.6	$	6.5	$	-0.5	$	26.6
		Accumulated Other Comprehensive Income (Loss)		Three months ended
				March 31,
				2013
		(In millions)		Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain (loss) from hedging instruments		Total
		Balance at beginning of period	$	-17.8	$	5.6	$	-1.1	$	-13.3
		Current increase (decrease)		-23.2		-0.3		0.2		-23.3
		Income tax (expense) benefit		-		-		-0.1		-0.1
		Balance at end of period		-41		5.3		-1		-36.7
		Other comprehensive income (loss) attributable to noncontrolling interests, net of tax		-0.3		-		-		-0.3
		Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	-40.7	$	5.3	$	-1	$	-36.4
		Accumulated Other Comprehensive Income (Loss)		Six months ended
				March 31,
				2014
		(In millions)		Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain (loss) from hedging instruments		Total
		Balance at beginning of period	$	2.9	$	6.4	$	-0.7	$	8.6
		Current increase (decrease)		17.7		0.1		0.2		18
		Balance at end of period		20.6		6.5		-0.5		26.6
		Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	20.6	$	6.5	$	-0.5	$	26.6
		Accumulated Other Comprehensive Income (Loss)		Six months ended
				March 31,
				2013
		(In millions)		Cumulative translation adjustments		Unrecognized elements of pension cost		Net gain (loss) from hedging instruments		Total
		Balance at beginning of period	$	-34	$	5.5	$	-1.2	$	-29.7
		Current increase (decrease)		-6.9		-0.2		0.4		-6.7
		Income tax (expense) benefit		-		-		-0.2		-0.2
		Balance at end of period		-40.9		5.3		-1		-36.6
		Other comprehensive income (loss) attributable to noncontrolling interests, net of tax		-0.2		-		-		-0.2
		Balance at end of period attributable to Sirona Dental Systems, Inc. shareholders	$	-40.7	$	5.3	$	-1	$	-36.4

Inventories_net_Tables

Inventories, net (Tables)	6 Months Ended
	Mar. 31, 2014
Inventories, net [Abstract]	'
Schedule of inventories, net	'
		Inventories		March 31,		September 30,
		(In millions)		2014		2013
		Finished goods	$	94.7	$	72.6
		Work in progress		13.2		14.4
		Raw materials		40.8		37.5
		Inventories, gross		148.7		124.5
		Inventory reserve		-19		-15.3
		Inventories, net	$	129.7	$	109.2

Intangible_Assets_and_Goodwill1

Intangible Assets and Goodwilll (Tables)	6 Months Ended
	Mar. 31, 2014
Intangible Assets And Goodwill [Abstract]	'
Schedule of finite-lived intangible assets by major class	'
		Intangible Assets		March 31,						September 30,
				2014						2013
						Accum.						Accum.
		(In millions)		Gross		amort.		Net		Gross		amort.		Net
		Patents & Licenses	$	155.5	$	-107.5	$	48	$	152.2	$	-99.1	$	53.1
		Trademarks		133.1		-0.8		132.3		130.8		-0.8		130
		Technologies and dealer relationships		498.3		-421.9		76.4		491.3		-403.2		88.1
		In-process research & development (IPR&D)		31.2		-		31.2		30.5		-		30.5
				818.1		-530.2		287.9		804.8		-503.1		301.7
		Goodwill		684.2		-		684.2		672.1		-		672.1
		Total intangible assets	$	1,502.30	$	-530.2	$	972.1	$	1,476.90	$	-503.1	$	973.8

ShortTerm_Financial_Liabilitie1

Short-Term Financial Liabilities (Tables)	6 Months Ended
	Mar. 31, 2014
Short-Term Financial Liabilities [Abstract]	'
Schedule of short-term financial liabilities	'
		Short-Term Financial Liabilities		March 31,		September 30,
		(In millions)		2014		2013
		Bank loans
		Accrued interest on long-term bank loans	$	0.3	$	0.3
		Other short-term bank loans		0.2		0.1
		Bank loans		0.5		0.4
		Other short-term financial liabilities		1.1		-
		Short-Term Financial Liabilities	$	1.6	$	0.4

Product_warranty_Tables

Product warranty (Tables)	6 Months Ended
	Mar. 31, 2014
Product warranty [Abstract]	'
Schedule of product warranty	'
		Product Warranty		Three months ended				Six months ended
				March 31,				March 31,
		(In millions)		2014		2013		2014		2013
		Balance at beginning of the period	$	10.2	$	8.5	$	9.7	$	8.5
		Accruals for warranties issued		4.9		5.3		10.5		9.2
		Warranty settlements made		-5.1		-4.9		-10.4		-8.9
		Translation adjustment		-		-0.2		0.2		-0.1
		Balance at end of the period	$	10	$	8.7	$	10	$	8.7

LongTerm_Financial_Liabilities1

Long-Term Financial Liabilities (Tables)	6 Months Ended
	Mar. 31, 2014
Long-Term Financial Liabilities [Abstract]	'
Schedule of long-term financial liabilities	'
		Long-Term Financial Liabilities		March 31,		September 30,
		(In millions, except percentages)		2014		2013
		Bank loans
		New Senior Term Loan ("Facility A" Term Loan, variable rate)
		repayable in two installments in November 2015 and November 2016	$	75.3	$	75.3
		(Actual interest rate as of March 31, 2014: 2.8775%)
		Bank loans		75.3		75.3
		Other long-term financial liabilities		3		-
				78.3		75.3
		Less current portion		-0.3		-0.3
		Long-Term Financial Liabilities	$	78	$	75

Pension_Plans_Tables

Pension Plans (Tables)	6 Months Ended
	Mar. 31, 2014
Pension Plans [Abstract]	'
Schedule of pension plans	'
		Components of Net Benefit Costs		Three months ended				Six months ended
				March 31,				March 31,
		(In millions)		2014		2013		2014		2013
		Service cost, net	$	-	$	-	$	-0.1	$	-0.1
		Interest cost		-0.6		-0.6		-1.1		-1.1
		Amortization of actuarial gain (loss)		-		-0.1		-0.1		-0.1
		Net periodic benefit cost	$	-0.6	$	-0.7	$	-1.3	$	-1.3

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Schedule of fair value by Balance Sheet grouping	'
		Assets and Liabilities Measured at Fair Value - Recurring Basis		March 31,
				2014
				Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
		(In millions)				Foreign Exchange
		Assets
		Cash Equivalents (money market funds)	$	137.7	$	-	$	-	$	137.7
		Derivative Assets		-		0.4		-		0.4
		Liabilities
		Derivative Liabilities		-		-0.4		-		-0.4
		Business Acquisition-related liabilities		-		-		-13.9		-13.9
		Total	$	137.7	$	-	$	-13.9	$	123.8
		Assets and Liabilities Measured at Fair Value - Recurring Basis		September 30,
				2013
				Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
		(In millions)				Foreign Exchange
		Assets
		Cash Equivalents (money market funds)	$	31.3	$	-	$	-	$	31.3
		Derivative Assets		-		0.9		-		0.9
		Liabilities
		Derivative Liabilities		-		-0.1		-		-0.1
		Business Acquisition-related liabilities		-		-		-13.4		-13.4
		Total	$	31.3	$	0.8	$	-13.4	$	18.7

Employee_ShareBased_Compensati2

Employee Share-Based Compensation (Details) (USD $)	6 Months Ended	12 Months Ended
	Mar. 31, 2014	Sep. 30, 2013
Equity incentive plan	'	'
Share-based compensation, options granted in period	224,565	'
Share-based compensation, grants in period weighted average exercised price	67.77	'
Share-based compensation, weighted average grant date fair value	21.28	'
Stock Options	'	'
Equity incentive plan	'	'
Share-based compensation, award vesting period	'4 years	'
Share-based compensation, options expiration date	'10 years	'
2006 Plan	'	'
Equity incentive plan	'	'
Share-based compensation, total number of stock options authorized	4,550,000	'
Share-based compensation, number of shares available for future grant	497,074	'
2006 Plan | RSU	'	'
Equity incentive plan	'	'
Granted, weighted average market price at grant	67.36	'
Granted, number of shares	149,469	'
2006 Plan | RSU | Minimum	'	'
Equity incentive plan	'	'
Share-based compensation, award vesting period	'3 years	'
2006 Plan | RSU | Maximum	'	'
Equity incentive plan	'	'
Share-based compensation, award vesting period	'4 years	'
2006 Plan | PSU	'	'
Equity incentive plan	'	'
Share-based compensation, award vesting period	'3 years	'
Granted, weighted average market price at grant	67.36	'
Granted, number of shares	43,466	'
2006 Plan | Stock Options	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]	'	'
Expected Volatility	33.27%	38.23%
Risk-free rate	1.35%	0.70%
Expected term	'5 years	'5 years
Expected dividends	0.00%	0.00%

Employee_ShareBased_Compensati3

Employee Share-Based Compensation (Details 1) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Compensation Expense	$3	$2.30	$6.40	$8.40
Compensation charge in connection with CFO and CEO and Chairman Transition	'	'	$0.90	$3.80

Employee_ShareBased_Compensati4

Employee Share-Based Compensation (Details 2) (USD $)	6 Months Ended
	Mar. 31, 2014
RSU	'
Restricted and Performance-Based Stock Unit Activity	'
Outstanding at beginning of period, number of shares	570,928
Granted, number of shares	149,469
Vested, number of shares	-182,329
Forfeited, number of shares	-23,615
Outstanding at end of period, number of shares	514,453
Outstanding at beginning of period, weighted average market price at grant	$46.37
Granted, weighted average market price at grant	$67.57
Vested, weighted average market price at grant	$37.68
Forfeited, weighted average market price at grant	$48.49
Outstanding at end of period, weighted average market price at grant	$55.51
PSU	'
Restricted and Performance-Based Stock Unit Activity	'
Outstanding at beginning of period, number of shares	13,000
Granted, number of shares	43,466
Vested, number of shares	-13,000
Forfeited, number of shares	0
Outstanding at end of period, number of shares	43,466
Outstanding at beginning of period, weighted average market price at grant	$36.78
Granted, weighted average market price at grant	$66.63
Vested, weighted average market price at grant	$36.78
Forfeited, weighted average market price at grant	$0
Outstanding at end of period, weighted average market price at grant	$66.63

Employee_ShareBased_Compensati5

Employee Share-Based Compensation (Details 3) (USD $)	6 Months Ended
	Mar. 31, 2014
Stock option activity	'
Outstanding at beginning of period, number of options	1,778,102
Granted, number of options	224,565
Exercised, number of options	-299,155
Forfeited, number of options	-28,900
Outstanding at end of period, number of options	1,674,612
thereof vested and exercisable	1,287,526
Stock option activity, weighted average exercise price	'
Outstanding at beginning of period, weighted average exercise price	$21.93
Granted, weighted avergae exercise price	$67.77
Exercised, weighted average exercise price	$17.67
Forfeited, weighted average exercise price	$51.68
Outstanding at end of period, weighted average exercise price	$28.33

Net_Other_Operating_Income_Los2

Net Other Operating Income (Loss)(Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Net Other Operating Income (Loss)[Abstract]	'	'	'	'
Income resulting from the amortization of the deferred income related to the Patterson exclusivity payment	$2.50	$2.50	$5	$5
Gain from patent infringement settlement	0	0	0	4.4
Net other operating income (loss)	$2.50	$2.50	$5	$9.40

Derivative_Instruments_and_Hed2

Derivative Instruments and Hedging Strategies (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Interest rate swap contracts	'	'	'	'
Interest Rate Risk	'	'	'	'
Percentage of Debt Hedged by Interest Rate Derivatives	100.00%	'	100.00%	'
Derivative, Lower Fixed Interest Rate Range	1.27%	'	1.27%	'
Derivative, Higher Fixed Interest Rate Range	1.29%	'	1.29%	'
Foreign Currency Exposure	'	'	'	'
Notional Amount	$55.40	'	$55.40	'
Interest rate swap contracts | Designated as Hedging Instrument	'	'	'	'
Impact of gains and losses from the fair value changes of the derivative instruments	'	'	'	'
Gain (Loss) Recognized in Accumulated Other Comprehensive Income	0.1	0.2	0.2	0.4
Foreign exchange contracts | Gain (loss) on derivative instruments | Not Designated as Hedging Instrument	'	'	'	'
Impact of gains and losses from the fair value changes of the derivative instruments	'	'	'	'
Gain (Loss) Recognized in Income	($1.50)	($2.50)	($0.90)	($1.20)

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Sep. 30, 2013
Income Taxes [Abstract]	'	'	'	'	'
Estimated effective tax rate	'	'	23.50%	24.00%	'
Income tax provision	$11.70	$10.20	$25.50	$25.40	'
Germany deferred tax remeasurement	'	2.2	'	'	'
Actual effective tax rate	'	'	'	'	23.70%
United States federal statutory rate	'	'	35.00%	'	'
Undistributed foreign earnings	$448	'	$448	'	'

Income_per_Share_Details

Income per Share (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Income per Share [Abstract]	'	'	'	'
Net income attributable to Sirona Dental Systems, Inc. common shareholders	$37.30	$31.80	$81.50	$70
Weighted average shares outstanding - basic	55,309,421	54,928,332	55,186,566	55,083,264
Dilutive effect of stock-based compensation	889,825	1,273,964	985,754	1,301,219
Weighted average shares - diluted	56,199,246	56,202,296	56,172,320	56,384,483
Net income per share	'	'	'	'
Basic	$0.67	$0.58	$1.48	$1.27
Diluted	$0.66	$0.56	$1.45	$1.24

Segment_reporting_Details

Segment reporting (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Revenue	'	'	'	'
Total	$282.70	$267.30	$581.40	$539.70
Dental CAD/CAM Systems	'	'	'	'
Revenue	'	'	'	'
Total	108.9	103.6	214.7	199.2
Segment Performance Measure	'	'	'	'
Total	73	69.8	146.3	137.4
Imaging Systems	'	'	'	'
Revenue	'	'	'	'
Total	87.9	83.6	193.7	180.6
Segment Performance Measure	'	'	'	'
Total	49.7	49.8	111.2	108.1
Treatment Centers	'	'	'	'
Revenue	'	'	'	'
Total	57.1	54.7	111.5	108.1
Segment Performance Measure	'	'	'	'
Total	23.5	21.9	44.7	43.1
Instruments	'	'	'	'
Revenue	'	'	'	'
Total	28.8	25.4	61.5	51.8
Segment Performance Measure	'	'	'	'
Total	11.2	10.8	24.7	23
Total segments	'	'	'	'
Segment Performance Measure	'	'	'	'
Total	$157.40	$152.30	$326.90	$311.60

Segment_reporting_Details_1

Segment reporting (Details 1) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Revenue	'	'	'	'
Consolidated revenue	$282.70	$267.30	$581.40	$539.70
Segement performance measure	'	'	'	'
Consolidated gross profit	151.5	144.7	314.2	296.6
Selling, general and administrative expense	-87.2	-84.5	-175.2	-170.4
Research and development expense	-16.4	-15.1	-31.5	-29.2
Net other operating income (loss)	2.5	2.5	5	9.4
Gain (loss) on foreign currency transactions	2	-1.4	-0.6	-6
Gain (loss) on derivative instruments	-1.5	-2.5	-0.9	-1.2
Interest income (expense)	-0.9	-0.8	-1.7	-1.8
Other income (expense)	-0.4	-0.4	-0.9	-0.7
INCOME BEFORE TAXES	49.6	42.5	108.4	96.7
Total segments	'	'	'	'
Segement performance measure	'	'	'	'
Consolidated gross profit	157.4	152.3	326.9	311.6
Dental CAD/CAM Systems	'	'	'	'
Revenue	'	'	'	'
Consolidated revenue	108.9	103.6	214.7	199.2
Imaging Systems	'	'	'	'
Revenue	'	'	'	'
Consolidated revenue	87.9	83.6	193.7	180.6
Treatment Centers	'	'	'	'
Revenue	'	'	'	'
Consolidated revenue	57.1	54.7	111.5	108.1
Instruments	'	'	'	'
Revenue	'	'	'	'
Consolidated revenue	28.8	25.4	61.5	51.8
Differences management reporting vs. US GAAP (including step-up depreciation and certain other corporate items)	'	'	'	'
Segement performance measure	'	'	'	'
Consolidated gross profit	($5.90)	($7.60)	($12.70)	($15)

Segment_reporting_Details_2

Segment reporting (Details 2) (USD $)

Mar. 31, 2014

Sep. 30, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

In Millions, unless otherwise specified

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Patterson Dental Company, Inc.

Patterson Dental Company, Inc.

Patterson Dental Company, Inc.

Patterson Dental Company, Inc.

Henry Schein, Inc.

Henry Schein, Inc.

Henry Schein, Inc.

Henry Schein, Inc.

Patterson Dental Company, Inc.

Patterson Dental Company, Inc.

Henry Schein, Inc.

Henry Schein, Inc.

Concentration Risk [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration Risk, Percentage

'

'

42.00%

47.00%

44.00%

47.00%

29.00%

32.00%

31.00%

33.00%

13.00%

15.00%

13.00%

14.00%

'

'

'

'

'

'

Accounts Receivable Net Current

$151

$145.20

'

'

'

'

'

'

'

'

'

'

'

'

$56

$53.90

$46.90

$45.70

$9.10

$8.20

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Loss) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Balance at beginning of period	$24.60	($13.30)	$8.60	($29.70)
Current increase / (decrease)	1.9	-23.3	18	-6.7
Income tax (expense) / benefit	'	-0.1	'	-0.2
Balance at end of period	26.5	-36.7	26.5	-36.7
Other comprehensive income (loss) attributable to noncontrolling interests, net of tax	-0.1	-0.3	'	-0.2
Balance at end of period attributable to Sirona Dental Systems, Inc.	26.6	-36.4	26.6	-36.4
Cumulated period computation	'	'	'	'
Balance at end of period	26.6	-36.6	26.6	-36.6
Cumulative translation adjustments	'	'	'	'
Balance at beginning of period	18.7	-17.8	2.9	-34
Current increase / (decrease)	1.8	-23.2	17.7	-6.9
Income tax (expense) / benefit	'	0	'	0
Balance at end of period	20.5	-41	20.5	-41
Other comprehensive income (loss) attributable to noncontrolling interests, net of tax	-0.1	-0.3	'	-0.2
Balance at end of period attributable to Sirona Dental Systems, Inc.	20.6	-40.7	20.6	-40.7
Cumulative translation adjustments | Cumulated period computation	'	'	'	'
Balance at end of period	20.6	-40.9	20.6	-40.9
Unrecognized elements of pension cost	'	'	'	'
Balance at beginning of period	6.5	5.6	6.4	5.5
Current increase / (decrease)	0	-0.3	0.1	-0.2
Income tax (expense) / benefit	'	0	'	0
Balance at end of period	6.5	5.3	6.5	5.3
Other comprehensive income (loss) attributable to noncontrolling interests, net of tax	0	0	'	0
Balance at end of period attributable to Sirona Dental Systems, Inc.	6.5	5.3	6.5	5.3
Unrecognized elements of pension cost | Cumulated period computation	'	'	'	'
Balance at end of period	6.5	5.3	6.5	5.3
Net gain (loss) from hedging instruments	'	'	'	'
Balance at beginning of period	-0.6	-1.1	-0.7	-1.2
Current increase / (decrease)	0.1	0.2	0.2	0.4
Income tax (expense) / benefit	'	-0.1	'	-0.2
Balance at end of period	-0.5	-1	-0.5	-1
Other comprehensive income (loss) attributable to noncontrolling interests, net of tax	0	0	'	0
Balance at end of period attributable to Sirona Dental Systems, Inc.	-0.5	-1	-0.5	-1
Net gain (loss) from hedging instruments | Cumulated period computation	'	'	'	'
Balance at end of period	($0.50)	($1)	($0.50)	($1)

Inventories_net_Details

Inventories, net (Details) (USD $)	Mar. 31, 2014	Sep. 30, 2013
In Millions, unless otherwise specified
Inventories, net [Abstract]	'	'
Finished goods	$94.70	$72.60
Work in progress	13.2	14.4
Raw materials	40.8	37.5
Inventory, gross	148.7	124.5
Inventory reserve	-19	-15.3
Inventories, net	$129.70	$109.20

Intangible_Assets_and_Goodwill2

Intangible Assets and Goodwill (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Sep. 30, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Total Intangible Assets excluding Goodwill, Gross	$818.10	$804.80
Finite-Lived Intangible Assets, Accumulated amortization	-530.2	-503.1
Intangible Assets, Net (Excluding Goodwill)	287.9	301.7
Goodwill	684.2	672.1
Total intangible assets, gross	1,502.30	1,476.90
Total intangible assets, accumulated amortization	-530.2	-503.1
Total intangible assets, net	972.1	973.8
Change In Goodwill And Intangible Assets [Abstract]	'	'
Finite Lived Intangible Assets, Translation Adjustments	15.6	'
In-process research and development	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	31.2	30.5
Finite-Lived Intangible Assets, Accumulated amortization	0	0
Intangible Assets, Net (Excluding Goodwill)	31.2	30.5
In-process research and development - Project 1	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	31.2	'
Change In Goodwill And Intangible Assets [Abstract]	'	'
Acquired Finite Lived Intangible Assets Estimated Cost To Complete Project	3	'
Acquired Finite Lived Intangible Assets Percentage Through Development Phase	65.00%	'
Acquired Finite Lived Intangible Assets Estimated Percentage Of Completion	50.00%	'
Patents & Licenses	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	155.5	152.2
Finite-Lived Intangible Assets, Accumulated amortization	-107.5	-99.1
Intangible Assets, Net (Excluding Goodwill)	48	53.1
Trademarks	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	133.1	130.8
Finite-Lived Intangible Assets, Accumulated amortization	-0.8	-0.8
Intangible Assets, Net (Excluding Goodwill)	132.3	130
Technologies and dealer relationships	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	498.3	491.3
Finite-Lived Intangible Assets, Accumulated amortization	-421.9	-403.2
Intangible Assets, Net (Excluding Goodwill)	$76.40	$88.10

ShortTerm_Financial_Liabilitie2

Short-Term Financial Liabilities (Details) (USD $)	Mar. 31, 2014	Sep. 30, 2013
In Millions, unless otherwise specified
Bank loans	'	'
Accrued interest on long-term bank loan	$0.30	$0.30
Other short-term bank loans	0.2	0.1
Bank loans	0.5	0.4
Other short-term financial liabilities	1.1	0
Short-Term Financial Liabilities	$1.60	$0.40

Product_Warranty_Details

Product Warranty (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Changes in the product warranty accrual	'	'	'	'
Balance at beginning of the period	$10.20	$8.50	$9.70	$8.50
Accruals for warranties issued	4.9	5.3	10.5	9.2
Warranty settlements made	-5.1	-4.9	-10.4	-8.9
Translation adjustment	0	-0.2	0.2	-0.1
Balance at end of the period	$10	$8.70	$10	$8.70

LongTerm_Financial_Liabilities2

Long-Term Financial Liabilities(Details)	Mar. 31, 2014	Sep. 30, 2013	Nov. 16, 2011	Mar. 31, 2014	Nov. 16, 2011	Mar. 31, 2014	Sep. 30, 2013	Nov. 16, 2011	Nov. 16, 2011
In Millions, unless otherwise specified	USD ($)	USD ($)	New Senior Facilities Agreement	New Senior Facilities Agreement	Facility A Term Loan	Facility A Term Loan	Facility A Term Loan	Revolving Facility B	Revolving Facility C
			USD ($)		New Senior Facilities Agreement	New Senior Facilities Agreement	New Senior Facilities Agreement	New Senior Facilities Agreement	New Senior Facilities Agreement
					USD ($)	USD ($)	USD ($)	EUR (€)	USD ($)
Bank loans:	'	'	'	'	'	'	'	'	'
Bank loans	$75.30	$75.30	'	'	'	$75.30	$75.30	'	'
Other long-term financial liabilities	3	0	'	'	'	'	'	'	'
Bank loans and other long-term financial liabilities	78.3	75.3	'	'	'	'	'	'	'
Less current portion	-0.3	-0.3	'	'	'	'	'	'	'
Long-term financial liabilities	78	75	'	'	'	'	'	'	'
Long-term debt, actual interest rate	'	'	'	'	'	2.88%	'	'	'
Senior Term Loans	'	'	'	'	'	'	'	'	'
Aggregate principal amount	'	'	'	'	75	'	'	120	100
Debt Instrument, Payment Terms	'	'	'	'	'Of the amount borrowed under the Facility A Term Loan, 30% is due on November 16, 2015, and the balance is due on NovemberB 16, 2016	'	'	'	'
Debt Instrument, Interest Rate Terms	'	'	'	'. The loans under the New Senior Facilities Agreement bear interest of EURIBOR, for Euro-denominated loans, and LIBOR for the other loans, plus an initial margin of 160, 85 and 110 basis points for the Facility A Term Loan, Revolving Facility B and Revolving Facility C, respectively	'	'	'	'	'
Debt Instrument, Interest Margin Ratchet Description	'	'	'The New Senior Facilities Agreement contains a margin ratchet. Pursuant to this provision, which applies from March 31, 2012 onwards, the applicable margin varies depending on the Companybs leverage multiple (i.e. the ratio of consolidated total net debt to consolidated adjusted EBITDA as defined in the New Senior Facilities Agreement) between 160 basis points and 215 basis points for the Facility A Term Loan, 85 basis points and 140 basis points for the Revolving Facility B, and 110 basis points and 165 basis points for the Revolving Facility C.	'	'	'	'	'	'
Deferred Finance Costs, Gross	'	'	$2.80	'	'	'	'	'	'
Nominal effective interest rate	1.28%	'	'	'	'	'	'	'	'

Pension_Plans_Details

Pension Plans (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Components of Net Benefit Costs	'	'	'	'
Service cost, net	$0	$0	($0.10)	($0.10)
Interest cost	-0.6	-0.6	-1.1	-1.1
Amortization of actuarial gains (loss)	0	-0.1	-0.1	-0.1
Net periodic benefit cost	($0.60)	($0.70)	($1.30)	($1.30)

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (Fair Value, Measurements, Recurring, USD $)	Mar. 31, 2014	Sep. 30, 2013
In Millions, unless otherwise specified
Assets	'	'
Cash Equivalents (money market funds)	$137.70	$31.30
Derivative Assets	0.4	0.9
Liabilities	'	'
Derivative Liabilities	-0.4	-0.1
Business Acquisition-related liabilities	-13.9	-13.4
Total	123.8	18.7
Quoted Prices in Active Markets for Identical Instruments (Level 1)	'	'
Assets	'	'
Cash Equivalents (money market funds)	137.7	31.3
Derivative Assets	0	0
Liabilities	'	'
Derivative Liabilities	0	0
Business Acquisition-related liabilities	0	0
Total	137.7	31.3
Significant Other Observable Inputs (Level 2) | Foreign exchange contracts	'	'
Assets	'	'
Cash Equivalents (money market funds)	0	0
Derivative Assets	0.4	0.9
Liabilities	'	'
Derivative Liabilities	-0.4	-0.1
Business Acquisition-related liabilities	0	0
Total	0	0.8
Significant Unobservable Inputs (Level 3)	'	'
Assets	'	'
Cash Equivalents (money market funds)	0	0
Derivative Assets	0	0
Liabilities	'	'
Derivative Liabilities	0	0
Business Acquisition-related liabilities	-13.9	-13.4
Total	($13.90)	($13.40)

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (USD $)	3 Months Ended	6 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2014
Fair Value Measurements [Abstract]	'	'
Income statement impact of the acquisition	$0.30	$0.70
Changes in fair value of contingent consideration	'	$0.50